This article has been updated to clarify the fact that Sigma-Aldrich is distributing antibodies derived from the HuCAL Gold library.
NEW YORK (GenomeWeb News) – MorphoSys said today it has agreed to a research antibody design and distribution agreement with Sigma-Aldrich.
Under the agreement, MorphoSys’s Serotec business unit will develop and qualify unique recombinant research antibodies from its HuCAL Gold library against targets identified by Sigma-Aldrich, which will distribute the antibodies, MorphoSys said.
Sigma-Aldrich will offer the HuCAL-based antibodies through its Antibody Explorer and Your Favorite Gene search platforms.
The HuCAL-based antibody technology “will allow researchers access to antibody content not available through standard antibody generation technologies,” said David Smoller, president of Sigma-Aldrich’s Research Biotech business unit.
Smoller also said that in conjunction with Sigma-Aldrich’s standard content generation capabilities, the research antibody technology “is expected to allow the community to reach its goal of a binder for every gene and one day even protein in the human body.”
Financial terms of the agreement were not released.